Encouraged by multiple positive clinical outcomes, a large-scale, randomized, double-blind, placebo-controlled, phase III ACE trial was initiated to confirm the efficacy of Tucidinostat plus Exemestane in patients with HR+/HER2- breast cancer, targeting postmenopausal women with HR+/HER2- breast cancer [90]. The gene discussed is ERBB2; the disease is breast cancer.